74
Markets2h 9m ago

Dyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.

Jupiter, Fla.

Who
Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic"), Mark A. Emalfarb, Scripps Research, CEPI, Fondazione Biotecnopolo di Siena, European Vaccines Hub, Proliant Health & Biologicals, Fermbox Bio, IBT Bioservices, Inzymes
What
Dyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.
When
Mon, 15 Jun 2026 11:28:03 GMT · 2h 9m ago
Where
Jupiter, Fla. ·
Why
The Bundibugyo Ebola virus outbreak has intensified global infectious disease preparedness efforts, bringing renewed attention to the need for rapid, scalable vaccine and antibody manufacturing.
The Frontline Impact

How this affects you

The increased focus on Dyadic's C1 platform for rapid and scalable biomanufacturing could accelerate the development of vaccines and antibodies during infectious disease outbreaks, potentially improving global health preparedness and response times, while also expanding commercial applications across life sciences, food, nutrition, and industrial markets.

Story chain

3 events in this thread
  1. Currently Reading2h 9m ago
    Dyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.
  2. Markets2h 9m ago
    Dyadic is highlighting increasing interest in its C1 protein production platform due to global infectious disease preparedness efforts responding to an ongoing Bundibugyo Ebola virus (BDBV) outbreak and expanding commercial adoption.
    Open article
  3. Markets2h 9m ago
    Dyadic's C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets.
    Open article

Verified Sources & Citations

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.